MNPR-101-Zr

About Monopar Therapeutics

Monopar Therapeutics is a clinical-stage biopharmaceutical company with a dual-pillar strategy focused on developing novel radiopharmaceuticals for oncology and a late-stage therapy for Wilson Disease. Its key achievement is the in-licensing of ALXN1840, which successfully met its primary endpoint in a Phase 3 trial, positioning it as a potential new standard of care. The company employs a capital-efficient, virtual operating model, drawing on a leadership team with a proven track record in rare disease drug development and commercialization to de-risk and accelerate its pipeline.

Therapeutic Areas